![]() |
|
|
Vol. 63, Issue 3, 557-564, March 2003
Cell Biology Section (D.N., M.S., J.S.K., A.M.J.) and Eicosanoid
Biochemistry Section (S.J.B., T.E.), Division of Intramural Research,
National Institute of Environmental Health Sciences, National
Institutes of Health, Research Triangle Park, North Carolina
In this study, we analyze the effect of several retinoids on the
expression of nonsteroidal anti-inflammatory drug-activated gene
(NAG-1) in normal human tracheobronchial epithelial
(HTBE) cells and several lung carcinoma cell lines. The retinoid
6-[3-(1-adamantyl)-4-hydroxyphenyl]-2-naphthalene carboxylic acid
(AHPN) greatly enhances the expression of NAG-1 mRNA and
protein in a time- and dose-dependent manner in human lung
adenocarcinoma H460 cells and several other carcinoma cell lines. This
induction was specific for AHPN because retinoic acid, a retinoic acid
receptor-, and a retinoid X receptor pan-agonist were unable to
induce NAG-1, suggesting that this induction is not
mediated through activation of retinoid receptors. Although NAG-1 is a p53-responsive gene, AHPN-induced
NAG-1 expression does not require p53. The induction of
NAG-1 expression by AHPN is caused at least in part by
an 8-fold increase in the stability of NAG-1 mRNA. In
contrast to carcinoma cells, NAG-1 expression is
effectively induced by retinoic acid and the RAR-selective pan-agonist
in normal HTBE cells and accompanies the inhibition of squamous
differentiation and the initiation of normal differentiation. In vivo,
NAG-1 expression was observed in the normal
tracheobronchial epithelium, whereas no expression was found in either
squamous metaplastic tracheal epithelium or in sections of human lung
tumors. Our results suggest that the induction of NAG-1
expression by retinoids in normal HTBE and lung carcinoma cells is
regulated by distinct mechanisms and is associated with different
biological processes. The linkage between AHPN treatment and
NAG-1 expression revealed in this study provides a new
mechanism for the antitumorigenic activity of AHPN.
This article has been cited by other articles:
![]() |
Y.-L. Chen, P.-C. Lin, S.-P. Chen, C.-C. Lin, N.-M. Tsai, Y.-L. Cheng, W.-L. Chang, S.-Z. Lin, and H.-J. Harn Activation of Nonsteroidal Anti-Inflammatory Drug-Activated Gene-1 via Extracellular Signal-Regulated Kinase 1/2 Mitogen-Activated Protein Kinase Revealed a Isochaihulactone-Triggered Apoptotic Pathway in Human Lung Cancer A549 Cells J. Pharmacol. Exp. Ther., November 1, 2007; 323(2): 746 - 756. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Soto-Cerrato, F. Vinals, J. R. Lambert, J. A. Kelly, and R. Perez-Tomas Prodigiosin induces the proapoptotic gene NAG-1 via glycogen synthase kinase-3{beta} activity in human breast cancer cells Mol. Cancer Ther., January 1, 2007; 6(1): 362 - 369. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. M. Martinez, T. Sali, R. Okazaki, C. Anna, M. Hollingshead, C. Hose, A. Monks, N. J. Walker, S. J. Baek, and T. E. Eling Drug-Induced Expression of Nonsteroidal Anti-Inflammatory Drug-Activated Gene/Macrophage Inhibitory Cytokine-1/Prostate-Derived Factor, a Putative Tumor Suppressor, Inhibits Tumor Growth J. Pharmacol. Exp. Ther., August 1, 2006; 318(2): 899 - 906. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-H. Lee, K. Yamaguchi, J.-S. Kim, T. E. Eling, S. Safe, Y. Park, and S. J. Baek Conjugated linoleic acid stimulates an anti-tumorigenic protein NAG-1 in an isomer specific manner Carcinogenesis, May 1, 2006; 27(5): 972 - 981. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Chintharlapalli, S. Papineni, S. J. Baek, S. Liu, and S. Safe 1,1-Bis(3'-indolyl)-1-(p-substitutedphenyl)methanes Are Peroxisome Proliferator-Activated Receptor {gamma} Agonists but Decrease HCT-116 Colon Cancer Cell Survival through Receptor-Independent Activation of Early Growth Response-1 and Nonsteroidal Anti-Inflammatory Drug-Activated Gene-1 Mol. Pharmacol., December 1, 2005; 68(6): 1782 - 1792. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Ferrari, U. Pfeffer, R. Dell'Eva, C. Ambrosini, D. M. Noonan, and A. Albini The Transforming Growth Factor-{beta} Family Members Bone Morphogenetic Protein-2 and Macrophage Inhibitory Cytokine-1 as Mediators of the Antiangiogenic Activity of N-(4-Hydroxyphenyl)Retinamide Clin. Cancer Res., June 15, 2005; 11(12): 4610 - 4619. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-S. Kim, S. J. Baek, T. Sali, and T. E. Eling The conventional nonsteroidal anti-inflammatory drug sulindac sulfide arrests ovarian cancer cell growth via the expression of NAG-1/MIC-1/GDF-15 Mol. Cancer Ther., March 1, 2005; 4(3): 487 - 493. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Baek, J.-S. Kim, S. M. Moore, S.-H. Lee, J. Martinez, and T. E. Eling Cyclooxygenase Inhibitors Induce the Expression of the Tumor Suppressor Gene EGR-1, Which Results in the Up-Regulation of NAG-1, an Antitumorigenic Protein Mol. Pharmacol., February 1, 2005; 67(2): 356 - 364. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Baek, J.-S. Kim, F. R. Jackson, T. E. Eling, M. F. McEntee, and S.-H. Lee Epicatechin gallate-induced expression of NAG-1 is associated with growth inhibition and apoptosis in colon cancer cells Carcinogenesis, December 1, 2004; 25(12): 2425 - 2432. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. Yamaguchi, S.-H. Lee, T. E. Eling, and S. J. Baek Identification of Nonsteroidal Anti-inflammatory Drug-activated Gene (NAG-1) as a Novel Downstream Target of Phosphatidylinositol 3-Kinase/AKT/GSK-3{beta} Pathway J. Biol. Chem., November 26, 2004; 279(48): 49617 - 49623. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. J. Baek, J.-S. Kim, J. B. Nixon, R. P. DiAugustine, and T. E. Eling Expression of NAG-1, a Transforming Growth Factor-{beta} Superfamily Member, by Troglitazone Requires the Early Growth Response Gene EGR-1 J. Biol. Chem., February 20, 2004; 279(8): 6883 - 6892. [Abstract] [Full Text] [PDF] |
||||